GLP1R agonists activate the cyclic AMP-dependent protein kinase A in the human airway and relax airway smooth muscle cells, thus proving GLP1 receptors to be potential targets for treating airway hyperresponsiveness [44]. The gene discussed is GLP1R; the disease is airway hyperresponsiveness.